Tocris Acquires Exclusive License for LDN 193189
Neural differentiation agent available from authorized commercial source for first time
Tocris Bioscience, part of the Biotechnology division of Bio-Techne, has signed an agreement with Brigham and Women's Hospital, Boston (USA), to acquire an exclusive license for LDN 193189. This compound was discovered by researchers at Brigham and Women's Hospital and Harvard Medical School and this license will enable researchers to purchase LDN 193189 from an authorized commercial source for the first time.
LDN 193189 is a bone morphogenetic protein (BMP) signaling inhibitor that can replace the endogenous BMP antagonist Noggin in protocols for generation of neurons from human pluripotent stem cells (hPSCs). The compound can also be used in combination with other small molecules to induce the differentiation of hPSCs into nociceptive sensory neurons.
Tocris' Head of Product Management, Robert Felix said, "We are very pleased to be able to offer LDN 193189 backed by the Tocris quality guarantee. The addition of this compound to the Tocris catalog complements our already extensive range of high quality stem cell products." It is the policy of Tocris to never knowingly infringe third party intellectual property. Our aim is to work with researchers to bring the latest, most innovative research tools out of the laboratory and into the research community. For more information regarding licensing at Tocris please visit www.tocris.com/licensing.
About Tocris Bioscience
Tocris Bioscience is part of the Biotechnology division of Bio-Techne. Our goal is to provide the global life science research community with the most innovative and high performing compounds to enable ground breaking discoveries. From its origins as a supplier of neuroscience research products, Tocris Bioscience has expanded to now offer innovative chemical tools for research in fields such as cancer, epigenetics and stem cells.
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. With thousands of products in its portfolio, Bio-Techne generated approximately $499 million in net sales in fiscal 2016 and has approximately 1,650 employees worldwide. For more information on Bio-Techne and its brands, please visit bio-techne.com.